The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Godkov M.A.

Sklifosovsky Research Institute For Emergency Medicine;
Russian Medical Academy of Continuous Professional Education

Shustov V.V.

Sklifosovsky Research Institute For Emergency Medicine

Dolya O.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology;
Peoples’ Friendship University of Russia

Sapozhnikova N.A.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

Polevshchikova S.A.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

Bazhenov A.I.

Sklifosovsky Research Institute For Emergency Medicine

Age features of immunity to SARS-CoV-2 of metropolis population in the dynamics

Authors:

Godkov M.A., Shustov V.V., Dolya O.V., Sapozhnikova N.A., Polevshchikova S.A., Bazhenov A.I.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2024;23(2): 118‑128

DOI: 10.17116/klinderma202423021118

Read: 1271 times

Download PDF (RU)
Contact the author
Table of contents

AGE FEATURES OF IMMUNITY TO SARS-COV-2 OF METROPOLIS POPULATION IN THE DYNAMICS
AGE FEATURES OF IMMUNITY TO SARS-COV-2 OF METROPOLIS POPULATION IN THE DYNAMICS

To cite this article:

Godkov MA, Shustov VV, Dolya OV, Sapozhnikova NA, Polevshchikova SA, Bazhenov AI. Age features of immunity to SARS-CoV-2 of metropolis population in the dynamics. Russian Journal of Clinical Dermatology and Venereology. 2024;23(2):118‑128. (In Russ.)
https://doi.org/10.17116/klinderma202423021118

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
IgM-dependent bullous pemphigoid. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):191-197
A rational approach to the prevention and treatment of ARVI and influenza, as a medico-economic and socially significant problem of the XXI century. Journal of Respiratory Medi­cine. 2025;(1):43-48
Post-COVID syndrome: orga­nizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medi­cine. 2025;(1):65-72
Post-Covid aortitis with cardiac invo­lvement: progressive aortic aneurysm combined with active myocarditis. Russian Journal of Archive of Pathology. 2025;(2):53-58
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Measles in the medi­cal community. Russian Journal of Preventive Medi­cine. 2025;(9):140-145
Cross-neutralizing acti­vity of a live intranasal vaccine based on the reco­mbinant Sendai virus of the Moscow strain against different variants of SARS-CoV-2. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4):39-47
A clinical case of severe influenza in an young healthy woman. Is vaccination nece­ssary for those outside of high-risk groups?. Russian Journal of Preventive Medi­cine. 2025;(12):109-117
Abstract:

INTRODUCTION

Large-scale vaccination is considered to be the most effective method of protection from infectious diseases. Vaccination implementation helps to increase population (community) immunity. The study of formation features of population immunity remains relevant task for understanding the course of epidemic process.

OBJECTIVE

To assess the dynamics and age features of community immunity formation to SARS-CoV-2 of metropolis population.

MATERIAL AND METHODS

A retrospective epidemiological study of serological screening was conducted. Results of laboratory examination of 2 903 747 patients (1 050 680 (36.2%) men and 1 853 067 (63.8%) women) for IgM and IgG antibodies to SARS-CoV-2 for 30 months were analyzed.

RESULTS

Decrease of IgM detection was found in two centralized laboratories during pandemic height. Combined detection of IgM/IgG in both laboratories had a similar undulating type of course. IgG detection has increased over time equivalently in each laboratory. There was an increase in the number of patients with high antibodies while assessing age-specific features of community immunity with age increase in 2020 and 2021 yrs. However, the trend has changed in 2022 yr. and there are no significant differences in the ratio of different age groups of patients with various rate of antibodies. Such changes happened in metropolis when new, more contagious version of SARS-CoV-2, namely Omicron, occurred.

CONCLUSIONS

The formation of a pronounced immune response in different age groups of patients of metropolis, especially in young population, most probably, caused by distribution of new version of SARS-CoV-2, namely Omicron, that may have affected secondary immune response activation in previously vaccinated or recovering patients in the city.

Keywords:

community immunity
IgM
IgG
SARS-CoV-2
new coronavirus infection
population immunity
vaccination
Omicron

Authors:

Godkov M.A.

Sklifosovsky Research Institute For Emergency Medicine;
Russian Medical Academy of Continuous Professional Education

Shustov V.V.

Sklifosovsky Research Institute For Emergency Medicine

Dolya O.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology;
Peoples’ Friendship University of Russia

Sapozhnikova N.A.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

Polevshchikova S.A.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology

Bazhenov A.I.

Sklifosovsky Research Institute For Emergency Medicine

Received:

27.11.2023

Accepted:

17.01.2024

Close metadata

References:

  1. COVID-19 Coronavirus pandemic. Accessed June 05, 2023. https://www.worldometers.info/coronavirus/#countries
  2. Briko NI, Kagramanyan IN, Nikiforov VV, Suranova TG, Chernyavskaya OP, Polezhaeva NA. Pandemic COVID-19. Prevention Measures in the Russian Federation. Epidemiology and Vaccinal Prevention. 2020;19(2):4-12. (In Russ.). https://doi.org/10.31631/2073-3046-2020-19-2-4-12
  3. Tsibin AN, Latypova MF, Ivanushkina OI. Confronting the Moscow Healthcare System with the Shocks of COVID-19. City Healthcare. 2021;2(1): 41-46. (In Russ.). https://doi.org/10.47619/2713-2617.zm.2021.v2i1;41-46
  4. Asatryan MN, Gerasimuk ER, Logunov DY, Semenenko TA, Gintsburg AL. Predicting the dynamics of Covid-19 incidence and planning preventive vaccination measures for Moscow population based on mathematical modeling. Journal of microbiology, epidemiology and immunobiology. 2020;97(4):289-302. (In Russ.). https://doi.org/10.36233/0372-9311-2020-97-4-1
  5. Medvedeva O, Nagibin O, Selyavina O. Experience of the response of healthcare systems in different countries at the beginning of the coronavirus pandemic (COVID-19). Public Health and Health Care. 2021;4(72):37-41. (In Russ.).
  6. Khudonogov I, Kremen E, Kremen S & Koloskova T. Medical efficacy of a spontaneous medico-social experiment (by the example of COVID-19 regional prevention). Siberian Journal of Life Sciences and Agriculture. 2022; 14(2):159-175. (In Russ.). https://doi.org/10.12731/2658-6649-2022-14-2-159-175
  7. Briko NI, Feldblum IV. Immunoprophylaxis of Infectious Diseases in Russia: Condition and Perspective of Improvement. Epidemiology and Vaccinal Prevention. 2017;16(2):4-9. (In Russ.).
  8. Korsak KS, Voropaev EV, Stoma IO. Analyzing the Problem of Mass Rejection of Vaccination against COVID-19. Possible Solutions. Epidemiology and Vaccinal Prevention. 2022;21(4):113-118. (In Russ.). https://doi.org/10.31631/2073-3046-2022-21-4-113-118
  9. Rodriguez-Morales AJ, Franco OH. Public trust, misinformation and COVID-19 vaccination willingness in Latin America and the Caribbean: today’s key challenges. Lancet Reg Health Am. 2021;3:100073. https://doi.org/10.1016/j.lana.2021.100073
  10. Fedorov VS, Ivanova ON, Karpenko IL, Ivanov AV. The Immune Response to the Novel Coronavirus Infection. Journal of Clinical Practice. 2021;12(1): 33-40. (In Russ.). https://doi.org/10.17816/clinpract64677
  11. Tan YJ, Goh PY, Fielding BC, et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol. 2004; 11(2):362-371. PMID: 15013989. https://doi.org/10.1128/cdli.11.2.362-371.2004
  12. Zhang X, Lu S, Li H, et al. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study. Virol Sin. 2020;35(6):820-829. PMID: 33351168. https://doi.org/10.1007/s12250-020-00329-9
  13. Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, et al. Antibody Responses in COVID-19: A Review. Front Immunol. 2021;12:633184. PMID: 33936045. https://doi.org/10.3389/fimmu.2021.633184
  14. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;71(15): 778-785. PMID: 32198501. https://doi.org/10.1093/cid/ciaa310
  15. Iyer AS, Jones FK, Nodoushani A, et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv. 2020;5(52): 2020.07.18.20155374. PMID: 32743600. https://doi.org/10.1101/2020.07.18.20155374
  16. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704. PMID: 32943637. https://doi.org/10.1038/s41467-020-18450-4
  17. Semmler G, Traugott MT, Graninger M, et al. Assessment of S1-, S2- and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays. J Clin Microbiol. 2021;59(5):e02890-20. PMID: 33161369. https://doi.org/10.1128/JCM.02890-20
  18. Maine GN, Lao KM, Krishnan SM, et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol. 2020;133:104663. PMID: 33161369. https://doi.org/10.1016/j.jcv.2020.104663
  19. Andreev AI, Andreev IV, Nechay KO, et al. The relationship between age and the intensity of the post-vaccination humoral immune response in individuals who have previously recovered from COVID-19. Immunology. 2022;43(5):583-592. (In Russ.). https://doi.org/10.33029/0206-4952-2022-43-5-583-592
  20. Mboumba Bouassa RS, Péré H, Tonen-Wolyec S, et al. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel. J Med Virol. 2021;93(4):2196-2203. PMID: 33107601. https://doi.org/10.1002/jmv.26628
  21. Sutovskaya DV, Burlutskaya AV, Dubova LV, et al. Immunogenicity, efficacy and tolerability of the Gam-Kovid-Vak vaccine among students: a prospective study. Pediatric pharmacology. 2022;19(2):196-200. (In Russ.). https://doi.org/10.15690/pf.v19i2.2401
  22. Platonova TA, Golubkova AA, Sklyar MS, Karbovnichaya EA, Smirnova SS. On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19. Epidemiology and Vaccinal Prevention. 2022;21(1):61-66. (In Russ.). https://doi.org/10.31631/2073-3046-2022-21-1-61-66
  23. Gracheva AV, Korchevaya ER, Kudryashova AM, Borisova OV, Petrusha OA, Smirnova DI, Chernyshova IN, Svitich OA, Zverev VV, Faizuloev EB. Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. Journal of microbiology, epidemiology and immunobiology. 2021;98(3):253-265. (In Russ.). https://doi.org/10.36233/0372-9311-136
  24. World Health Organization Population-Based Age-Stratified Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID-19) Infection, 26 May 2020. Version 2.0. Accessed Jun 06, 2023. https://apps.who.int/iris/handle/10665/332188
  25. Andryukov BG, Lyapun IN. COVID-19 diagnostic laboratory strategies: modern technologies and development trends (review of literature). Klinicheskaya Laboratornaya Diagnostika (Russian Clinical Laboratory Diagnostics). 2020;65(12):757-766. (In Russ.). https://doi.org/10.18821/0869-2084-2020-65-12-757-766
  26. Gorbunov AA, Sorokina LE, Chegodar DV, et al. Diagnostics of COVID-19: current state of the problem and prospects in the industry. Crimean Journal of Experimental and Clinical Medicine. 2020;10(2):69-77. (In Russ.).
  27. Kuzin SN, Semenenko TA, Klushkina VV, Vlasenko NV, Churilova NS, Panasyuk YV, Kudryavtseva EN, Korabel’nikova MI, Dubodelov DV, Rodionova ZS, Solopova GG, Konopliova MV, Nikitin IG, Shulakova NI, Tutelian AV, Akimkin VG. Herd Immunity to Hepatitis B in the Russian Federation in 2017–2019. Epidemiology and Vaccinal Prevention. 2022;21(2):2937. (In Russ.). https://doi.org/10.31631/2073-3046-2022-21-2-29-37
  28. Popova AYu, Totolyan AA. Methodology for assessing population immunity to the SARS-COV-2 virus in the context of the COVID-19 pandemic. Infektsiya i immunitet. 2021;11(4):609-616. (In Russ.). https://doi.org/10.15789/2220-7619-MFA-1770
  29. Popova AYu, Ezhlova EB, Mel’nikova AA, i dr. Population immunity to SARS-COV-2 among the population of St. Petersburg during the COVID-19 epidemic. Problemy osobo opasnykh infektsii. 2020;3:124-130. (In Russ.). https://doi.org/10.21055/0370-1069-2020-3-124-130
  30. Medunitsyn NV, Olefir YuV, Merkulov VA, Bondarev VP. Vaccination contribute to the development of personal and herd immunity. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(4):195-207. (In Russ.).
  31. Coronavirus. Online map of the spread of coronavirus. Coronavirus in Russia and the world. Accessed June 05, 2023. (In Russ.). https://coronavirus-control.ru
  32. Coronavirus today — statistics and monitoring on the map online (official website). Accessed June 05, 2023. (In Russ.). https://koronavirustoday.ru
  33. Coronavirus COVID-19. Statistics. Accessed June 05, 2023. (In Russ.). https://news.mail.ru/coronavirus/stat/world/
  34. Yang HS, Costa V, Racine-Brzostek SE, et al. Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021;4(3):e214302. PMID: 33749770. https://doi.org/10.1001/jamanetworkopen.2021.4302
  35. Godkov MA, Shustov VV, Kasholkina EA. Dynamics and gender and age features of the COVID-19 EPIDEMIC process in Moscow (results of screening survey for 1.5 years). Laboratory Service. 2021;10(4):30-37. (In Russ.). https://doi.org/10.17116/labs20211004130
  36. Holwerda TJ, Jaarsma E, van Zutphen EM, et al. The impact of COVID-19 related adversity on the course of mental health during the pandemic and the role of protective factors: a longitudinal study among older adults in The Netherlands. Soc Psychiatry Psychiatr Epidemiol. 2023:1-12. PMID: 36964770. https://doi.org/1010.1007/s00127-023-02457-5
  37. Lee PI, Hu YL, Chen PY, et al. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53(3):371-372. PMID: 32147409. https://doi.org/10.1016/j.jmii.2020.02.011
  38. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children Fare Better than Adults? Indian J Pediatr. 2020;87(7):537-546. PMID: 32410003. https://doi.org/10.1007/s12098-020-03322-y
  39. Piccaluga PP, Malerba G, Navari M, et al. Cross-Immunization Against Respiratory Coronaviruses May Protect Children From SARS-CoV2: More Than a Simple Hypothesis? Front Pediatr. 2021;8:595539. PMID: 33537261. https://doi.org/10.3389/fped.2020.595539
  40. Asamoah-Boaheng M, Grunau B, Karim ME, et al. Are higher antibody levels against seasonal human coronaviruses associated with a more robust humoral immune response after SARS-CoV-2 vaccination? Front Immunol. 2022;13:954093. PMID: 36159791. https://doi.org/10.3389/fimmu.2022.954093
  41. Komarov AG, Tarnovetsky IYu, Speshilov GI, et al. Epidemiological monitoring of patients with coronavirus infection based on modern molecular biological research methods in 2021-2022. in the metropolis. Tuberculosis and socially significant diseases. 2022;10(3):35-43. (In Russ.).
  42. Briko NI, Korshunov VA, Krasnova SV, Protsenko DN, Glazovskaya LS, Gostishchev RV, Saltykova TS, Chernyavskaya OP, Pozdnyakov AA, Labanovich VV, Kaneev AI. Clinical and epidemiological characteristics of hospitalized patients with COVID-19 during different pandemic periods in Moscow. Journal of microbiology, epidemiology and immunobiology. 2022;99(3): 287-299. (In Russ.). https://doi.org/10.36233/0372-9311-272
  43. Vechorko VI, Averkov OV, Zimin AA. New SARS-CoV-2 Omicron variant — clinical picture, treatment, prevention (literature review). Cardiovascular Therapy and Prevention. 2022;21(6):89-98. (In Russ.). https://doi.org/10.15829/1728-8800-2022-3228
  44. The number of people vaccinated against coronavirus in Moscow. Accessed June 05, 2023. (In Russ.). https://gogov.ru/covid-v-stats/msk#data
  45. Shustov VV, Tsibin AN, Gushchin VA, Petrikov SS, Godkov MA. Gender and age features of the formation of a humoral immune response to COVID-19 vaccination. Laboratory Service. 2022;11(3):17-23. (In Russ.). https://doi.org/10.17116/labs20221103117
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.